International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy

Authors: Dacic, Sanja, Travis, William, Redman, Mary, Saqi, Anjali, Cooper, Wendy A., Borczuk, Alain, Chung, Jin-Haeng, Glass, Carolyn, Lopez, Javier Martin, Roden, Anja C., Sholl, Lynette, Weissferdt, Annikka, Posadas, Juan, Walker, Angela, Zhu, Hu, Wijeratne, Manuja T., Connolly, Casey, Wynes, Murry, Bota-Rabassedas, Neus, Sanchez-Espiridion, Beatriz, Lee, J.Jack, Berezowska, Sabina, Chou, Teh-Ying, Kerr, Keith, Nicholson, Andrew, Poleri, Claudia, Schalper, Kurt A., Tsao, Ming-Sound, Carbone, David P., Ready, Neal, Cascone, Tina, Heymach, John, Sepesi, Boris, Shu, Catherine, Rizvi, Naiyer, Sonett, Josuha, Altorki, Nasser, Provencio, Mariano, Bunn, Paul A., Jr., Kris, Mark G., Belani, Chandra P., Kelly, Karen, Wistuba, Ignacio

Source: In Journal of Thoracic Oncology October 2023 18(10):1290-1302

Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

Authors: Dercle, Laurent, Fronheiser, Matthew, Rizvi, Naiyer A., Hellmann, Matthew D., Maier, Sabine, Hayes, Wendy, Yang, Hao, Guo, Pingzhen, Fojo, Tito, Schwartz, Lawrence H., Zhao, Binsheng, Leung, David K.

Source: In Journal of Thoracic Oncology May 2023 18(5):587-598

Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice

Authors: Saqi, Anjali, Leslie, Kevin O., Moreira, Andre L., Lantuejoul, Sylvie, Shu, Catherine Ann, Rizvi, Naiyer A., Sonett, Joshua R., Tajima, Kosei, Sun, Shawn W., Gitlitz, Barbara J., Colby, Thomas V.

Source: In JTO Clinical and Research Reports May 2022 3(5)

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)

Authors: Garon, Edward B., Cho, Byoung Chul, Reinmuth, Niels, Lee, Ki Hyeong, Luft, Alexander, Ahn, Myung-Ju, Robinet, Gilles, Le Moulec, Sylvestre, Natale, Ronald, Schneider, Jeffrey, Shepherd, Frances A., Garassino, Marina Chiara, Geater, Sarayut Lucien, Szekely, Zsolt Papai, Van Ngoc, Tran, Liu, Feng, Scheuring, Urban, Patel, Nikunj, Peters, Solange, Rizvi, Naiyer A.

Source: In Clinical Lung Cancer July 2021 22(4):301-312

Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases

Authors: Tagore, Somnath, Caprio, Lindsay, Amin, Amit Dipak, Bestak, Kresimir, Luthria, Karan, D’Souza, Edridge, Barrera, Irving, Melms, Johannes C., Wu, Sharon, Abuzaid, Sinan, Wang, Yiping, Jakubikova, Viktoria, Koch, Peter, Brodtman, D. Zack, Bawa, Banpreet, Deshmukh, Sachin K., Ebel, Leon, Ibarra-Arellano, Miguel A., Jaiswal, Abhinav, Gurjao, Carino, Biermann, Jana, Shaikh, Neha, Ramaradj, Priyanka, Georgis, Yohanna, Lagos, Galina G., Ehrlich, Matthew I., Ho, Patricia, Walsh, Zachary H., Rogava, Meri, Politis, Michelle Garlin, Biswas, Devanik, Cottarelli, Azzurra, Rizvi, Nikhil, Shu, Catherine A., Herzberg, Benjamin, Anandasabapathy, Niroshana, Sledge, George, Zorn, Emmanuel, Canoll, Peter, Bruce, Jeffrey N., Rizvi, Naiyer A., Taylor, Alison M., Saqi, Anjali, Hibshoosh, Hanina, Schwartz, Gary K., Henick, Brian S., Chen, Fei, Schapiro, Denis, Shah, Parin, Izar, Benjamin

Source: Nature Medicine; 20250101, Issue: Preprints p1-13, 13p

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Authors: Sezer, Ahmet ^*, Kilickap, Saadettin, Gümüş, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M, Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip, Sriuranpong, Virote, Rizvi, Naiyer, Gao, Bo, Li, Siyu, Lee, Sue, McGuire, Kristina, Chen, Chieh-I, Makharadze, Tamta, Paydas, Semra, Nechaeva, Marina, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Gullo, Giuseppe, Lowy, Israel, Rietschel, Petra

Source: In The Lancet 13-19 February 2021 397(10274):592-604

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Authors: Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., Awad, Mark M.

Source: In JTO Clinical and Research Reports November 2020 1(4)

Characteristics and outcomes of lung cancer in solid organ transplant recipients

Authors: Chen, Lanyi Nora, Spivack, John, Cao, Thu, Saqi, Anjali, Benvenuto, Luke J., Bulman, William A., Mathew, Matthen, Stoopler, Mark B., Arcasoy, Selim M., Stanifer, Bryan P., Rizvi, Naiyer A., Shu, Catherine A. ^*

Source: In Lung Cancer August 2020 146:297-302

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Authors: Shu, Catherine A, Gainor, Justin F, Awad, Mark M, Chiuzan, Codruta, Grigg, Claud M, Pabani, Aliyah, Garofano, Robert F, Stoopler, Mark B, Cheng, Simon K, White, Abby, Lanuti, Michael, D'Ovidio, Frank, Bacchetta, Matthew, Sonett, Joshua R, Saqi, Anjali, Rizvi, Naiyer A ^*

Source: In The Lancet Oncology June 2020 21(6):786-795

Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

Authors: Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., Awad, Mark M.

Source: In JTO Clinical and Research Reports June 2020

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

Authors: Sridhar, Sriram, Paz-Ares, Luis, Liu, Hao, Shen, Kui, Morehouse, Chris, Rizvi, Naiyer, Segal, Neil H., Jin, Xiaoping, Zheng, Yanan, Narwal, Rajesh, Gupta, Ashok, Dennis, Phillip A., Ye, Jiabu, Mukhopadhyay, Pralay, Higgs, Brandon W., Ranade, Koustubh

Source: In Clinical Lung Cancer November 2019 20(6):e601-e608

Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib

Authors: Camidge, D. Ross, Pabani, Aliyah, Miller, Ronni M., Rizvi, Naiyer A., Bazhenova, Lyudmila

Source: In Journal of Thoracic Oncology September 2019 14(9):1547-1555

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

Authors: Boothman, Anne-Marie, Scott, Marietta, Ratcliffe, Marianne, Whiteley, Jessica, Dennis, Phillip A., Wadsworth, Catherine, Sharpe, Alan, Rizvi, Naiyer A., Garassino, Marina Chiara, Walker, Jill

Source: In Journal of Thoracic Oncology August 2019 14(8):1390-1399

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Authors: Skoulidis, Ferdinandos, Araujo, Haniel A., Do, Minh Truong, Qian, Yu, Sun, Xin, Cobo, Ana Galan, Le, John T., Montesion, Meagan, Palmer, Rachael, Jahchan, Nadine, Juan, Joseph M., Min, Chengyin, Yu, Yi, Pan, Xuewen, Arbour, Kathryn C., Vokes, Natalie, Schmidt, Stephanie T., Molkentine, David, Owen, Dwight H., Memmott, Regan, Patil, Pradnya D., Marmarelis, Melina E., Awad, Mark M., Murray, Joseph C., Hellyer, Jessica A., Gainor, Justin F., Dimou, Anastasios, Bestvina, Christine M., Shu, Catherine A., Riess, Jonathan W., Blakely, Collin M., Pecot, Chad V., Mezquita, Laura, Tabbó, Fabrizio, Scheffler, Matthias, Digumarthy, Subba, Mooradian, Meghan J., Sacher, Adrian G., Lau, Sally C. M., Saltos, Andreas N., Rotow, Julia, Johnson, Rocio Perez, Liu, Corinne, Stewart, Tyler, Goldberg, Sarah B., Killam, Jonathan, Walther, Zenta, Schalper, Kurt, Davies, Kurtis D., Woodcock, Mark G., Anagnostou, Valsamo, Marrone, Kristen A., Forde, Patrick M., Ricciuti, Biagio, Venkatraman, Deepti, Van Allen, Eliezer M., Cummings, Amy L., Goldman, Jonathan W., Shaish, Hiram, Kier, Melanie, Katz, Sharyn, Aggarwal, Charu, Ni, Ying, Azok, Joseph T., Segal, Jeremy, Ritterhouse, Lauren, Neal, Joel W., Lacroix, Ludovic, Elamin, Yasir Y., Negrao, Marcelo V., Le, Xiuning, Lam, Vincent K., Lewis, Whitney E., Kemp, Haley N., Carter, Brett, Roth, Jack A., Swisher, Stephen, Lee, Richard, Zhou, Teng, Poteete, Alissa, Kong, Yifan, Takehara, Tomohiro, Paula, Alvaro Guimaraes, Parra Cuentas, Edwin R., Behrens, Carmen, Wistuba, Ignacio I., Zhang, Jianjun, Blumenschein, George R., Gay, Carl, Byers, Lauren A., Gibbons, Don L., Tsao, Anne, Lee, J. Jack, Bivona, Trever G., Camidge, D. Ross, Gray, Jhannelle E., Leighl, Natasha B., Levy, Benjamin, Brahmer, Julie R., Garassino, Marina C., Gandara, David R., Garon, Edward B., Rizvi, Naiyer A., Scagliotti, Giorgio Vittorio, Wolf, Jürgen, Planchard, David, Besse, Benjamin, Herbst, Roy S., Wakelee, Heather A., Pennell, Nathan A., Shaw, Alice T., Jänne, Pasi A., Carbone, David P., Hellmann, Matthew D., Rudin, Charles M., Albacker, Lee, Mann, Helen, Zhu, Zhou, Lai, Zhongwu, Stewart, Ross, Peters, Solange, Johnson, Melissa L., Wong, Kwok K., Huang, Alan, Winslow, Monte M., Rosen, Michael J., Winters, Ian P., Papadimitrakopoulou, Vassiliki A., Cascone, Tina, Jewsbury, Philip, Heymach, John V.

Source: Nature; November 2024, Vol. 635 Issue: 8038 p462-471, 10p

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Authors: Alban, Tyler J., Riaz, Nadeem, Parthasarathy, Prerana, Makarov, Vladimir, Kendall, Sviatoslav, Yoo, Seong-Keun, Shah, Rachna, Weinhold, Nils, Srivastava, Raghvendra, Ma, Xiaoxiao, Krishna, Chirag, Mok, Juk Yee, van Esch, Wim J. E., Garon, Edward, Akerley, Wallace, Creelan, Benjamin, Aanur, Nivedita, Chowell, Diego, Geese, William J., Rizvi, Naiyer A., Chan, Timothy A.

Source: Nature Medicine; November 2024, Vol. 30 Issue: 11 p3209-3222, 14p

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

Authors: Garassino, Marina Chiara, Cho, Byoung-Chul, Kim, Joo-Hang, Mazières, Julien, Vansteenkiste, Johan, Lena, Hervé, Jaime, Jesus Corral, Gray, Jhanelle E., Powderly, John, Chouaid, Christos, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Soo, Ross A., Poole, Lynne, Wadsworth, Catherine, Dennis, Phillip A., Rizvi, Naiyer A.

Source: Lung cancer. 147:137-142

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121114074.0x000001&indx=1&recIds=ETOCvdc_100121114074.0x000001

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Authors: Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2018 Oct . 115(43), E10119-E10126.

Access URL: https://www.jstor.org/stable/26532386

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Authors: Blumenthal, Gideon M., Bunn, Paul A., Jr., Chaft, Jamie E., McCoach, Caroline E., Perez, Edith A., Scagliotti, Giorgio V., Carbone, David P., Aerts, Hugo J.W.L., Aisner, Dara L., Bergh, Jonas, Berry, Donald A., Jarkowski, Anthony, Botwood, Nicholas, Cross, Darren A.E., Diehn, Max, Drezner, Nicole L., Doebele, Robert C., Blakely, Collin M., Eberhardt, Wilfried E.E., Felip, Enriqueta, Gianni, Luca, Keller, Steven P., Leavey, Patrick J., Malik, Shakun, Pignatti, Francesco, Prowell, Tatiana M., Redman, Mary W., Rizvi, Naiyer A., Rosell, Rafael, Rusch, Valerie, de Ruysscher, Dirk, Schwartz, Lawrence H., Sridhara, Rajeshwari, Stahel, Rolf A., Swisher, Stephen, Taube, Janis M., Travis, William D., Keegan, Patricia, Wiens, Jacinta R., Wistuba, Ignacio I., Wynes, Murry W., Hirsch, Fred R., Kris, Mark G.

Source: In Journal of Thoracic Oncology December 2018 13(12):1818-1831

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Authors: Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q.M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke, Roel, Rizvi, Naiyer A.

Source: In Journal of Thoracic Oncology November 2018 13(11):1733-1742

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Authors: Gettinger, Scott, Hellmann, Matthew D., Chow, Laura Q.M., Borghaei, Hossein, Antonia, Scott, Brahmer, Julie R., Goldman, Jonathan W., Gerber, David E., Juergens, Rosalyn A., Shepherd, Frances A., Laurie, Scott A., Young, Tina C., Li, Xuemei, Geese, William J., Rizvi, Naiyer

Source: In Journal of Thoracic Oncology September 2018 13(9):1363-1372